ASTIMS: : Autologous Stem cell Transplantation International Multiple Sclerosis
A multicenter, prospective randomized phase II study to compare efficacy and safety of high dose immunoablation and autologous hematopoietic stem cell transplantation (ASCT) with Mitoxantrone drug therapy for the treatment of patients with severe multiple sclerosis.
study for patients suffering from severe forms of multiple sclerosis
The ASTIMS Trial is an international clinical study for patients suffering from severe forms of multiple sclerosis. The study compares two treatments with respect to their beneficial effect on the disease course as well as their safety:
- 1. intensive immunosuppression followed by autologous stem cell transplantation
(ASCT), considered the investigative treatment
- 2. the immunosuppressive drug Mitoxantrone (administered in monthly doses for 6 consecutive months), considered the control treatment.